Mavenclad

Cladribine, the active ingredient in Mavenclad, is a purine nucleoside analog presented as a 10 mg tablet for oral use. It is indicated for the treatment of relapsing forms of multiple sclerosis in adults, helping to reduce disease activity and slow disability progression.

GNH USA supplies Mavenclad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution networks across Europe, Asia and the Americas, meeting stringent quality standards for the reliable provision of essential global medicines.

Mavenclad is used as a disease‑modifying therapy for multiple sclerosis, targeting the relapsing disease process.

Relapsing‑remitting multiple sclerosis (RRMS): reduces annual relapse rate and slows accumulation of disability. Secondary progressive multiple sclerosis with active disease (SPMS): decreases relapse frequency and mitigates disability progression. Relapsing forms of multiple sclerosis (overall): serves as an immunomodulatory therapy to lower disease activity and delay progression.

Cladribine may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Lymphopenia: reduced lymphocyte counts often observed during treatment. - Headache: mild to moderate headache reported by patients. - Nausea: occasional nausea, usually transient. - Fatigue: general tiredness or lack of energy.

Serious or Rare Side Effects: - Severe lymphopenia: profound depletion of lymphocytes increasing infection risk. - Opportunistic infections: including herpes zoster or fungal infections. - Hepatic injury: elevated liver enzymes or hepatitis. - Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal brain infection.

When prescribing Cladribine, several precautions and warnings should be observed to ensure patient safety.

Pregnancy: contraindicated; risk of fetal harm classified as Category D. Breastfeeding: not recommended; drug may be excreted in breast milk. Infection risk: monitor for signs of infection and postpone treatment if active infection is present. Blood counts: perform regular monitoring of lymphocyte and complete blood counts during and after therapy. Vaccination: avoid live vaccines during treatment and for several weeks after the last dose. Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Cladribine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Live vaccines: concurrent use may cause severe infection; avoid during and after therapy. - Immunosuppressive agents: combined use can markedly increase risk of profound lymphopenia and infection.

Moderate Interactions (Monitor Closely): - Antiviral drugs (e.g., acyclovir): may require dose adjustment due to overlapping immunosuppressive effects. - CYP450 inhibitors: potential to increase Cladribine plasma levels, monitor for toxicity. - Vaccines containing attenuated organisms: schedule appropriately to reduce infection risk.